PBAC's latest decision on Trastuzumab: Recommended (2021). Considered for Treatment of metastatic (Stage IV) HER2 positive breast cancer, metastatic (Stage IV) HER2 positive adenocarcinoma of the stomach or gastro-oesophageal junction, early HER2 positive breast cancer, and locally advanced HER2 positive breast cancer. This submission concerns a new 440 mg vial size.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
13
first 2006
Submissions
13
2006 → 2021
Eligible population
Patients with HER2 positive breast cancer (metastatic, early, or locally advanced) and HER2 positive adenocarcinoma of the stomach or gastro-oesophageal junction, already eligible for trastuzumab under existing PBS codes.
Cost-minimisation analysis; no ICER calculated as this is a new vial size of an existing listed drug assessed on a cost-neutral basis.
ICER (historical)
$45k/QALY–$75k/QALY across 4 submissions (2006–2015) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.